TRICIA CARVALHO: Open Payments
NPI 1043533508 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,395 in 162 payments from 20 companies in 2025. Trend: 2023 $1,652 · 2024 $3,674 · 2025 $3,395
Food & beverage: $3,395
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 14 | $572 |
| Janssen Biotech, Inc. | 18 | $451 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $415 |
| PFIZER INC. | 30 | $398 |
| ABBVIE INC. | 17 | $377 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 16 | $283 |
| GENZYME CORPORATION | 7 | $217 |
| Ardelyx, Inc. | 15 | $195 |
| Celltrion USA Inc. | 6 | $106 |
| Lilly USA, LLC | 2 | $60 |
Products named: REZDIFFRA, TREMFYA, XIFAXAN, ENTYVIO, VELSIPITY, DUPIXENT, IBSRELA, XELJANZ.
Industry payments across MD — which companies pay providers there.
